Episurf Medical’s implants receive national regulatory approval in Hong Kong

Report this content

Episurf Medical (NASDAQ: EPIS B) today announces that the Department of Health (Medical Device Division) in Hong Kong has approved the company’s implant technologies Episealer® Knee and Episealer® Talus for the Hong Kong market. Included in the approval is also the ankle device Talus Osteotomy Guide. The approval follows a review process. 

“Previously we were able to act in this market thanks to our CE marked products, but it brought on various limitations. This national approval is important, and it will help us increase the market acceptance in the region even further”, says Michael Näsström, Head of Quality and Regulatory Affairs at Episurf Medical.  

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET on 18 February 2022.